These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23918069)

  • 1. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.
    Lenihan DJ; Kowey PR
    Oncologist; 2013; 18(8):900-8. PubMed ID: 23918069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
    Shah RR; Morganroth J; Shah DR
    Drug Saf; 2013 May; 36(5):295-316. PubMed ID: 23620167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.
    Shah RR; Morganroth J
    Drug Saf; 2015 Aug; 38(8):693-710. PubMed ID: 26008987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects.
    Liu C; Amin R; Shatila M; Short N; Altan M; Shah A; Alhalabi O; Okhuysen P; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3965-3976. PubMed ID: 36030431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interactions in patients using tyrosine kinase inhibitors: A multicenter retrospective study.
    Ergun Y; Yildirim Ozdemir N; Toptas S; Kurtipek A; Eren T; Yazici O; Sendur MA; Akinci B; Ucar G; Oksuzoglu B; Uncu D
    J BUON; 2019; 24(4):1719-1726. PubMed ID: 31646831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs.
    Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
    J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.
    Totzeck M; Mincu RI; Mrotzek S; Schadendorf D; Rassaf T
    Eur J Prev Cardiol; 2018 Mar; 25(5):482-494. PubMed ID: 29376753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
    Dasanu CA; Padmanabhan P; Clark BA; Do C
    Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.
    Rimassa L; Danesi R; Pressiani T; Merle P
    Cancer Treat Rev; 2019 Jul; 77():20-28. PubMed ID: 31195212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
    Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
    Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
    Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN
    Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis.
    Ciccarese C; Anghelone A; Stefani A; Cigliola A; Strusi A; D'Agostino F; Bria E; Iacovelli R; Tortora G
    Expert Rev Anticancer Ther; 2024 Jul; 24(7):623-633. PubMed ID: 38879826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
    Malkan UY; Haznedaroglu IC
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.
    Brown SA; Nhola L; Herrmann J
    Clin Pharmacol Ther; 2017 Jan; 101(1):65-80. PubMed ID: 27806435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.
    Ekram J; Rathore A; Avila C; Hussein R; Alomar M
    Cancer Control; 2024; 31():10732748241285755. PubMed ID: 39318033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linking MedDRA(®)-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors.
    Sarntivijai S; Zhang S; Jagannathan DG; Zaman S; Burkhart KK; Omenn GS; He Y; Athey BD; Abernethy DR
    Drug Saf; 2016 Jul; 39(7):697-707. PubMed ID: 27003817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.
    Li J; Gu J
    Clin Drug Investig; 2018 Dec; 38(12):1109-1123. PubMed ID: 30327999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.